Literature DB >> 19735987

Hereditary spastic paraplegia and axonal motor neuropathy caused by a novel SPG3A de novo mutation.

Carlo Fusco1, Daniele Frattini, Enrico Farnetti, Davide Nicoli, Bruno Casali, Francesco Fiorentino, Andrea Nuccitelli, Elvio Della Giustina.   

Abstract

Mutations in the SPG3A gene (atlastin protein) cause approximately 10% of autosomal-dominant hereditary spastic paraplegia. Most patients with an SPG3A mutation present with a pure phenotype and early-onset disease, although complicated forms with peripheral neuropathy are also reported. We report a new heterozygous S398F mutation in exon 12 of the SPG3A gene causing a very early-onset spastic paraplegia in association with motor axonal neuropathy in a 4-year-old girl resembling diplegic cerebral palsy. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735987     DOI: 10.1016/j.braindev.2009.08.003

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  9 in total

1.  De novo mutations in SPG3A: a challenge in differential diagnosis and genetic counselling.

Authors:  Luca Leonardi; Christian Marcotulli; Filippo M Santorelli; Alessandra Tessa; Carlo Casali
Journal:  Neurol Sci       Date:  2015-01-31       Impact factor: 3.307

2.  Zebrafish atlastin controls motility and spinal motor axon architecture via inhibition of the BMP pathway.

Authors:  Coralie Fassier; James A Hutt; Steffen Scholpp; Andrew Lumsden; Bruno Giros; Fatiha Nothias; Sylvie Schneider-Maunoury; Corinne Houart; Jamilé Hazan
Journal:  Nat Neurosci       Date:  2010-10-10       Impact factor: 24.884

3.  Clinical features and genotype-phenotype correlation analysis in patients with ATL1 mutations: A literature reanalysis.

Authors:  Guo-Hua Zhao; Xiao-Min Liu
Journal:  Transl Neurodegener       Date:  2017-04-04       Impact factor: 8.014

4.  Extensive In Silico Analysis of ATL1 Gene : Discovered Five Mutations That May Cause Hereditary Spastic Paraplegia Type 3A.

Authors:  Mujahed I Mustafa; Naseem S Murshed; Abdelrahman H Abdelmoneim; Miyssa I Abdelmageed; Nafisa M Elfadol; Abdelrafie M Makhawi
Journal:  Scientifica (Cairo)       Date:  2020-04-19

5.  Swimming in Deep Water: Zebrafish Modeling of Complicated Forms of Hereditary Spastic Paraplegia and Spastic Ataxia.

Authors:  Valentina Naef; Serena Mero; Gianluca Fichi; Angelica D'Amore; Asahi Ogi; Federica Gemignani; Filippo M Santorelli; Maria Marchese
Journal:  Front Neurosci       Date:  2019-12-10       Impact factor: 4.677

6.  De novo pathogenic variant in SETX causes a rapidly progressive neurodegenerative disorder of early childhood-onset with severe axonal polyneuropathy.

Authors:  Aristides Hadjinicolaou; Kathie J Ngo; Daniel Y Conway; John P Provias; Steven K Baker; Lauren I Brady; Craig L Bennett; Albert R La Spada; Brent L Fogel; Grace Yoon
Journal:  Acta Neuropathol Commun       Date:  2021-12-18       Impact factor: 7.801

7.  Hereditary neuropathy with liability to pressure palsy (HNPP): report of a family with a new point mutation in PMP22 gene.

Authors:  Carlo Fusco; Carlotta Spagnoli; Grazia Gabriella Salerno; Elena Pavlidis; Daniele Frattini; Francesco Pisani
Journal:  Ital J Pediatr       Date:  2017-10-27       Impact factor: 2.638

8.  ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot-Marie-Tooth disease.

Authors:  Celeste Montecchiani; Lucia Pedace; Temistocle Lo Giudice; Antonella Casella; Marzia Mearini; Fabrizio Gaudiello; José L Pedroso; Chiara Terracciano; Carlo Caltagirone; Roberto Massa; Peter H St George-Hyslop; Orlando G P Barsottini; Toshitaka Kawarai; Antonio Orlacchio
Journal:  Brain       Date:  2015-11-10       Impact factor: 13.501

9.  Long-term follow-up until early adulthood in autosomal dominant, complex SPG30 with a novel KIF1A variant: a case report.

Authors:  Carlotta Spagnoli; Susanna Rizzi; Grazia Gabriella Salerno; Daniele Frattini; Carlo Fusco
Journal:  Ital J Pediatr       Date:  2019-12-03       Impact factor: 2.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.